Features | Partner Sites | Information | LinkXpress
Sign In
RG Advertising
TeraRecon
Schiller

Imaging for Amyloid Deposits Also Shows Promise for Detecting Cardiac Amyloidosis

By Medimaging International staff writers
Posted on 21 Feb 2013
Whereas amyloid imaging may now be most associated with detecting plaques in the brain, it also has the potential to alter the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research, positron emission tomography (PET) with 11C-PIB (Pittsburgh compound B) can effectively visualize amyloid deposits in the heart. Currently, there is no other noninvasive test available for specific diagnosis.

The study’s findings were published in the February 2013 issue of the Journal of Nuclear Medicine. Cardiac amyloidosis is a deadly disorder caused by abnormal amyloid deposits in the heart tissue. Early diagnosis before structural change to the heart tissue has occurred is important for disease prognosis and for treatment monitoring. Echocardiography is the current mainstay of imaging in cardiac amyloidosis; a cardiac biopsy is used to validate diagnosis.

“Imaging with 11C-PIB provides a noninvasive and specific means of showing distribution of amyloid in an organ. This gives a unique opportunity to follow and monitor therapy, as amyloid deposits in the heart should decrease with successful therapy,” said Gunnar Antoni, PhD, from department of medicinal chemistry, Uppsala University (Sweden), and lead author of the research.

The study included 10 patients diagnosed with cardiac amyloidosis and five healthy individuals. PET/computed tomography (CT) with 11C-PIB was used to visualize amyloid deposits in the heart and with 11C-acetate to measure myocardial blood flow.

Uptake of 11C-PIB was measured 15–25 minutes after injection. Obvious uptake of 11C-PIB was noted in the left ventricle wall of all patients with cardiac amyloidosis, while no uptake was seen in the healthy volunteers. In half of the patients, 11C-PIB was also detected in the right ventricle wall, and nine of the patients had signs of reversible uptake, with a maximum concentration at 10–15 minutes after injection. Myocardial blood flow was significantly lower in patients with cardiac amyloidosis; however, no significant correlation between myocardial blood flow and 11C-PIB uptake was found.

“This study emphasizes the strength of molecular imaging for detecting an underlying and significant molecular aberration in a disease that presents with unspecific symptoms and signs,” noted Dr. Antoni. “The potential for molecular imaging to provide valuable information for other diseases is of great value to the field of medicine.”

Related Links:
Uppsala University






Channels

MRI

view channel
Image: Construction Workers Building CUBRIC (Photo courtesy of Cardiff University).

New Brain Research Imaging Center Under Construction in Cardiff University

Cardiff University (Cardiff, UK) has begun building an advanced MR imaging technology center, with the help of Siemens Healthcare (Erlangen, Germany). The center will use the latest brain imaging and brain... Read more

General/Advanced Imaging

view channel
Image: Measuring the Magnetic Activity in the Brain of a Child, Using a MEG machine. (Photo courtesy of Children\'s Hospital of Philadelphia).

Study Suggests Language Delay Linked to Chromosome Deletion in Children with Neurological Disorders

A study found that children with neuro-developmental problems born with DNA duplications or deletions on part of chromosome 16, show measurable delays in their ability to process sound and language.... Read more

Imaging IT

view channel

European Governments Adopting Country-Specific Electronic Health Record Implementation Models

Frost & Sullivan (Mountain View, CA, USA) has released a new analysis of the Electronic Health Records (EHR) market in Europe. The study analyzes the hospital and ambulatory EHR market. According to the study, the market earned revenues of USD 2.74 billion in 2014, and is expected to reach USD 3.69 billion in 2020.... Read more

Industry News

view channel

Long-Term Contract for Telehealth Services Awarded by German Health Insurance Company

Almeda (Munich, Germany), a subsidiary of SHL Telemedicine (Tel Aviv, Israel), has won a public tender for an 8-year contract worth EUR 16–20 million offered by Barmer GEK (Wuppertal, Germany), a health insurance company, to provide telehealth services to clients insured at Barmer. Barmer GEK was already a long-term client... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.